Clinical Trials Logo

Vaccine Preventable Diseases clinical trials

View clinical trials related to Vaccine Preventable Diseases.

Filter by:

NCT ID: NCT06357650 Not yet recruiting - COVID-19 Clinical Trials

Collaborative Open Research Initiative Study (CORIS-1)

CORIS-1
Start date: June 1, 2024
Phase:
Study type: Observational

The Collaborative Open Research Initiative Study (CORIS) is a groundbreaking international research endeavor aimed at exploring vital topics within the field of health professions education. At its core, CORIS embodies the spirit of inclusivity by opening its doors to contributors from all corners of the globe, putting the power of research into the hands of the global community and fostering an environment of open collaboration and meaningful contribution. We invite anyone and everyone to join as collaborators and suggest questions for inclusion in the survey, ensuring that the research process is enriched by diverse perspectives. As a collaborator, you will not only have the opportunity to actively engage in survey design, question formulation, and the entire research process from start to finish, but also gain the prospect of achieving valuable publications, which may boost your professional career.

NCT ID: NCT06333275 Recruiting - Clinical trials for Vaccine Immunity in CAR-T Cell Therapy Recipients

Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy

IMCAR
Start date: November 14, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about vaccine immunity in patients with B-cell malignancies treated by chimeric antigen receptor T-cell therapies (CAR-T). The main questions it aims to answer are: - Do CAR-T cell therapy recipients lose vaccine protection against common vaccine-preventable pathogens - Are current re-vaccination recommendations sufficient in restoring vaccine-protection - Is this restored vaccine-protection after CAR-T cell therapy lost faster than usual - Do clinical or immunological factors predict vaccine response after CAR-T cell therapy

NCT ID: NCT06298708 Not yet recruiting - Hepatitis A Clinical Trials

Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents

HAV-RCT
Start date: April 2024
Phase: Phase 3
Study type: Interventional

Hepatitis A virus (HAV) vaccine is an effective strategy to prevent natural HAV infection. In Thailand, there are 2 types of HAV vaccine available, including inactivated HAV vaccine and live-attenuated HAV vaccine. This study aims to compare the immunogenicity and safety of inactivated and lived-attenuated HAV vaccine among Thai healthy children and adolescents age 18 months to 18 years.

NCT ID: NCT06202703 Recruiting - Clinical trials for Vaccine-Preventable Diseases

Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity

SEA
Start date: April 15, 2023
Phase: N/A
Study type: Interventional

Rationale Causing a wide range of infectious diseases, including pneumonia, otitis media and meningitis, S. pneumoniae represents an important global health problem. Pneumococcal vaccines are clinically effective in preventing invasive pneumococcal disease, but the underlying immune response is likely to differ due to the inclusion of T cell epitopes in the conjugate, but not purified polysaccharide vaccine. However, these differences remain scantly studied. Lymph node fine needle aspiration (FNA) has been recently described to study vaccine-induced germinal centre responses in depth and represents a promising tool to study the underlying immune mechanisms of pneumococcal vaccines. Insight into the underlying immune mechanisms of vaccines could improve future vaccine design, e.g. by refining dosing intervals. Objective Determine timing of peak germinal centre B cell frequency following pneumococcal vaccination. Main trial endpoints The main trial endpoint is represented by the frequency of germinal centre B cells (BGC) in lymph node aspirates at various time points after vaccination, as measured by spectral flow cytometry. Both total BGC cells and S. pneumoniae polysaccharide-specific BGC frequencies will be determined. Trial design Pilot intervention study without a comparator. Trial population Healthy individuals between the age of 20 - 40 Interventions Subjects will be vaccinated once with Prevenar13. FNA of the draining lymph node will be performed and blood will be drawn at baseline, followed by weekly collection during the first four weeks, every other week between weeks 4 - 8 and a final collection time point after 12 weeks, resulting in a total of 8 sampling time points over the course of three months. Draining lymph node size will be assessed by ultrasound every other day during the first two weeks and then alongside lymph node FNA for the remainder of the study.

NCT ID: NCT06162676 Not yet recruiting - HPV Infection Clinical Trials

Game-Based Intervention to Promote HPV Vaccination

Start date: December 2023
Phase: N/A
Study type: Interventional

This study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote HPV vaccination; will explore changes in key outcomes and related measures; and will identify factors contributing to or impeding effective implementation in health clinic settings. The intervention and its approach have the potential to reduce health disparities in HPV-associated cancers in youth via low-cost technology and timely intervention.

NCT ID: NCT06147895 Completed - Hepatitis B Clinical Trials

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine

CVI-HBV-002
Start date: September 17, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-HBV-002.

NCT ID: NCT06137755 Recruiting - Herpes Zoster Clinical Trials

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

Start date: March 15, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.

NCT ID: NCT06124131 Completed - Colorectal Cancer Clinical Trials

Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

BENEFIT-C
Start date: November 11, 2023
Phase: N/A
Study type: Interventional

The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are: - Do patient financial incentives for completing colorectal cancer screening increase screening completion? - Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots? Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment. Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.

NCT ID: NCT06104345 Recruiting - Cholera Clinical Trials

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

Start date: October 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years. The main question it aims to answer is: • Does coadministration impact the immune responses to Vivotif® and Dukoral® vaccines Participants will: - receive either oral typhoid fever (Vivotif®) or oral cholera (Dukoral®) vaccines or both simultaneously - give blood samples for immunogenicity analyses - participate in adverse event follow up Researchers will compare those receiving only one of the vaccines to those receiving both simultaneously to see if coadministration has an impact on antigen-specific responses measured with: - ELISPOT (plasmablast responses specific to Salmonella typhi, Vibrio Cholerae and Enterotoxigenic Escherichia coli) - ELISA (antibodies in lymphocyte supernatants (ALS) and serum antibodies specific to vaccine antigens)

NCT ID: NCT06098690 Not yet recruiting - Clinical trials for Health Knowledge, Attitudes, Practice

Culturally Tailored HPV Psychoeducational Multimedia Intervention

Start date: June 2024
Phase: N/A
Study type: Interventional

Community members ages 18 - 45 years old from the El Paso, Texas, U.S.-Mexico Border Region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (HPV). Our hypothesis is that adults who view culturally tailored multimedia stories encouraging HPV vaccination will report higher vaccine uptake rates.